Search Results
219 results
Your search is now limited to «Gilead» expert search.
ENDPOINTS 03/20/2019 08:53
Gilead’s 2019 forecast — issued last month — implied “product sales growth of -2% to +0.5%, suggesting that overall Gilead ‘s business has finally plateaued,” Nadeau added.
More from ENDPOINTS:
Zacks.com 03/19/2019 17:45
In the latest trading session, Gilead Sciences ( GILD - Free Report) closed at $65.49, marking a +0.72% move from the previous day.
More from Zacks.com:
FiercePharmaManufacturing 03/18/2019 11:33
RELATED: Gilead's top executives Milligan and Martin stepping down Milligan’s accelerated options were valued at $5.8 million when Gilead and its now-former CEO inked the severance deal sometime after he announced his exit in July.
More from FiercePharmaManufacturing:
Contract Pharma 03/14/2019 09:34
Agenus Inc. , an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies, said the FDA accepted the company's IND filing for AGEN1423—a milestone in its partnership with Gilead that triggered a cash payment of $7.5 million.
More from Contract Pharma:
WN.com 03/13/2019 09:43
LEXINGTON, Mass., March 13, 2019 /PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, announced today that the FDA has accepted the company's IND filing for AGEN1423 - a milestone in its partnership with Gilead Sciences, Inc. This milestone triggered a cash payment of $7.5M.
More from WN.com:
Seeking Alpha 03/12/2019 15:35
Gilead Sciences, Inc. (NASDAQ:GILD) Barclays Global Healthcare Conference Call March 12, 2019 10:45 AM ET Company Participants Robin Washington - CFO John McHut.
More from Seeking Alpha:
FierceMedicalDevices 03/08/2019 05:16
Teams at Gilead, Pfizer and other research groups have spent years looking into the capsid that cloaks the genetic material of HIV.
More from FierceMedicalDevices:
Gilead has initiated a Phase 1b study of GS-6207 in people living with HIV.
More from Pharmaceutical Business Review:
Korean Biomedical Review 03/08/2019 01:35
Yuhan Corp. said Friday that it has signed an agreement with Gilead Science Korea to co-promote Biktarvy, the latter’s human immunodeficiency virus (HIV) treatment, from this month.
More from Korean Biomedical Review:
Pharmafile 03/07/2019 11:10
Having joined Gilead in 2017, Dr Riva played a critical role in driving the expansion of the Californian firm’s oncology programs.
More from Pharmafile:
All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
More from Global Banking & Finance Review:
Xconomy 03/06/2019 16:57
Xconomy San Francisco — The oncology division of Gilead Sciences (NASDAQ: GILD) is losing two of its leaders.
More from Xconomy:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications